摘要银屑病是一种免疫介导的慢性炎症性皮肤病,白介素-12和白介素-23在银屑病发病中起到重要作用.乌司奴单抗作为一种人源化单克隆抗体,能与白介素-12和白介素-23共有的p40亚基特异性结合,阻断各自介导的免疫反应,用于银屑病的治疗.临床试验表明,该药具有良好的耐受性,不良反应轻微,并且疗效迅速、显著,能改善生活质量.目前资料证明,该药适用于成人中重度斑块状银屑病治疗,也可用于其他类型银屑病的治疗.

abstractsPsoriasis is a chronic,immune-mediated inflammatory skin disease.Interleukin (IL)-12 and IL-23 play an important role in the pathogenesis of psoriasis.Ustekinumab,as a humanized monoclonal antibody,can block IL-12-and IL-23-mediated responses by binding to the p40 subunit shared by IL-12 and IL-23,and,hence,can be used for the treatment of psoriasis.Clinical trials have shown that ustekinumab has a marked and sustained efficacy with rapid-onset of action,good tolerability and mild adverse reactions.Moreover,ustekinumab has been recommended for the treatment of moderate-to-severe plaque psoriasis in adults,as well as other types of psoriasis.